# Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma

> **NCT04073147** · PHASE1 · TERMINATED · sponsor: **Klinikum Stuttgart** · enrollment: 4 (actual)

## Conditions studied

- Primary CNS Lymphoma

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT04073147
- **Lead sponsor:** Klinikum Stuttgart
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-12
- **Primary completion:** 2021-11-25
- **Final completion:** 2021-11-25
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** low recruitment
- **Last updated:** 2022-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04073147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04073147, "Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04073147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*